Why Ipamorelin Is the 'Cleanest' GHRP

Ipamorelin

200x dose

Ipamorelin did not raise ACTH or cortisol even at doses more than 200-fold higher than the effective GH-releasing dose, a selectivity no other GHRP has matched.

Raun et al., Eur J Endocrinol, 1998

Raun et al., Eur J Endocrinol, 1998

View as image

Every growth hormone releasing peptide activates the ghrelin receptor. Every one of them triggers a burst of growth hormone from the pituitary. But most of them also push up cortisol, ACTH, and prolactin. Ipamorelin does not. In a 1998 pharmacological study that defined the compound, Raun et al. showed that ipamorelin released growth hormone with potency comparable to GHRP-6, but did not raise ACTH or cortisol at any tested dose, even at concentrations more than 200-fold higher than the effective dose for GH release.^[1]

That selectivity is why ipamorelin is called the "cleanest" GHRP. The term is not marketing language. It refers to a specific, measurable pharmacological property: the ability to release growth hormone without activating the hypothalamic-pituitary-adrenal axis or stimulating prolactin secretion. No other growth hormone releasing peptide has demonstrated this separation across a comparable dose range.

What "Clean" Means in Growth Hormone Pharmacology

Growth hormone releasing peptides work by binding the growth hormone secretagogue receptor (GHS-R1a), the same receptor that the endogenous hormone ghrelin activates. The receptor sits on somatotroph cells in the anterior pituitary, and activating it triggers GH release. But GHS-R1a is not exclusive to somatotrophs. It is also expressed on corticotroph cells (which produce ACTH, the upstream driver of cortisol) and on lactotroph cells (which produce prolactin).^[1]

When GHRP-6 or GHRP-2 binds GHS-R1a, the signal cascade activates all three cell types. You get GH release, but you also get ACTH and prolactin release. This is why studies of GHRP-6 report strong hunger, cortisol elevation, and modest prolactin increases alongside the desired GH pulse.

Ipamorelin binds the same receptor but produces a different downstream signal. The GH release is preserved. The ACTH and prolactin release is absent. The exact mechanism of this selectivity is not fully resolved, but it likely involves biased agonism: the peptide stabilizes a receptor conformation that preferentially activates somatotroph-specific signaling pathways while failing to trigger the signaling cascades in corticotrophs and lactotrophs.^[1]

The 200-Fold Dose Test

The landmark study by Raun et al. tested ipamorelin against GHRP-6 and GHRP-2 across a wide dose range in conscious swine. All three compounds released GH with similar potency. Ipamorelin had an ED50 of 2.3 nmol/kg and a maximal GH response of 65 ng/ml plasma. GHRP-6 was comparable (ED50 3.9 nmol/kg, Emax 74 ng/ml). GHRP-2 was more potent (ED50 0.6 nmol/kg) but had lower maximal efficacy (Emax 56 ng/ml).^[1]

The critical finding was what happened beyond GH. Administration of both GHRP-6 and GHRP-2 increased plasma ACTH and cortisol. Ipamorelin did not. The authors then pushed ipamorelin's dose to more than 200-fold above its ED50 for GH release. Still no statistically significant increase in ACTH or cortisol above baseline GHRH-stimulation levels. None of the three peptides affected FSH, LH, PRL, or TSH at any dose.^[1]

This dose-selectivity ratio has not been replicated by any other GHRP in a published comparative study. It means that even accidental overdosing of ipamorelin would not be expected to drive cortisol spikes, a safety margin that GHRP-2 and GHRP-6 cannot claim.

How Ipamorelin Differs from GHRP-6 and GHRP-2

Arvat et al. quantified the hormonal side effects of non-selective GHRPs in a 1997 human study. They administered GHRP-2 and hexarelin (a GHRP-6 analog) to healthy young and elderly adults and measured GH, prolactin, ACTH, and cortisol responses. Both peptides produced strong GH release that exceeded GHRH. Both also increased ACTH and cortisol at levels comparable to human corticotropin-releasing hormone (hCRH), and both raised prolactin, though less than TRH.^[2]

This study established the baseline that ipamorelin departs from. For a detailed breakdown of how GHRP-2 and GHRP-6 compare to each other, their cortisol and prolactin profiles are a key differentiator. But the more fundamental distinction is between the non-selective group (GHRP-2, GHRP-6, hexarelin) and ipamorelin, which stands alone in its GH specificity. A full side-by-side analysis is covered in Ipamorelin vs Other GHRPs.

Non-peptide secretagogues like MK-677 also raise IGF-1 through the same receptor pathway but share the non-selective profile: MK-677 increases cortisol and appetite alongside GH elevation.

The Structural Chemistry Behind Selectivity

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was derived from GHRP-1 through a systematic chemistry program that removed the central Ala-Trp dipeptide. This deletion produced a smaller molecule that retained full GH-releasing efficacy but lost the ability to stimulate ACTH and cortisol.^[1]

The structure contains two non-natural amino acids (Aib and D-2-Nal) and two D-amino acids (D-2-Nal and D-Phe). These modifications serve a dual purpose. The D-amino acids resist enzymatic degradation by proteases that target natural L-amino acid peptide bonds, extending the functional half-life. The Aib (alpha-aminoisobutyric acid) residue constrains the peptide backbone into conformations that favor GHS-R1a binding in a somatotroph-selective orientation.^[1]

The Raun et al. study confirmed that ipamorelin, like GHRP-6, works through a GHRP-type receptor rather than the GHRH receptor, as demonstrated by antagonist profiling. This means the selectivity difference is not a matter of receptor type. Both ipamorelin and GHRP-6 hit the same receptor. The difference is in how the receptor responds to each ligand, a concept now understood as biased agonism. Ahnfelt-Ronne et al. further showed that NN703, an orally active compound derived from ipamorelin via peptidomimetic development, entered Phase II clinical trials, demonstrating the translational potential of this structural approach.^[3]

Human Pharmacokinetics: What Happens After Injection

Gobburu et al. modeled ipamorelin's pharmacokinetics and pharmacodynamics in human volunteers using a dose-escalation design with five infusion rates (4.21 to 140.45 nmol/kg over 15 minutes) in eight healthy male subjects per dose level. The pharmacokinetic parameters showed dose proportionality: terminal half-life of 2 hours, clearance of 0.078 L/h/kg, and volume of distribution at steady state of 0.22 L/kg. The concentration required for half-maximal GH stimulation (SC50) was 214 nmol/L, with a maximal GH production rate of 694 mIU/L/h.^[4]

The GH release profile showed a single episode of secretion peaking at approximately 40 minutes after infusion, followed by an exponential decline. This pulsatile pattern mimics the body's natural GH secretion more closely than continuous elevation, which is associated with side effects. Ipamorelin's 2-hour half-life means it clears quickly, allowing the pituitary to recover its normal sensitivity before the next dose.

Johansen et al. separately evaluated ipamorelin's pharmacokinetics in rats and found a systemic clearance 5-fold lower than GHRP-6 (ipamorelin was primarily excreted renally, while GHRP-6 was excreted via bile). Ipamorelin also showed approximately 20% intranasal bioavailability and 60-80% recovery as intact peptide from bile and urine combined, indicating moderate resistance to metabolic degradation.^[5]

Functional Outcomes: Bone Growth and GI Motility

Selectivity is pharmacologically elegant, but the practical question is whether ipamorelin's GH release translates into tissue-level effects. Two lines of evidence address this.

Johansen et al. administered ipamorelin subcutaneously three times daily for 15 days to adult female rats at doses of 18, 90, and 450 micrograms/day. Longitudinal bone growth rate increased dose-dependently from 42 micrometers/day in controls to 44, 50, and 52 micrometers/day in treatment groups (P < 0.0001). Body weight gain also increased dose-dependently. The GH-releasing effect did not desensitize over the 15-day period, a critical finding for any peptide intended for repeated administration.^[6]

Separately, Venkova et al. tested ipamorelin in a rodent model of postoperative ileus (the gut paralysis that commonly follows abdominal surgery). Repetitive dosing of ipamorelin (0.1 or 1 mg/kg, four doses daily at 3-hour intervals for 2 days) significantly increased cumulative fecal output, food intake, and body weight gain compared to vehicle. This GI prokinetic effect operates through the ghrelin receptor pathway, the same mechanism by which ghrelin stimulates gut motility, and led to clinical interest in ipamorelin for post-surgical recovery.^[7]

What "Clean" Does Not Mean

Ipamorelin's selectivity is about the absence of cortisol, ACTH, and prolactin elevation. It does not mean the peptide has no biological effects beyond GH release. Any compound that elevates growth hormone will secondarily increase IGF-1, which carries its own set of biological consequences. Ipamorelin also activates the ghrelin receptor in the gut, as the Venkova data shows, meaning it has prokinetic effects that may or may not be desired.

The published ipamorelin literature is also weighted toward acute pharmacological studies and short-term animal experiments. The Raun 1998 paper, the Gobburu 1999 human PK study, and the Johansen bone growth study collectively involve days to weeks of observation. Long-term human data from controlled trials is limited, and the selective profile demonstrated in acute dosing has not been confirmed in studies spanning months or years.

Additionally, the claim of selectivity rests on the specific hormonal endpoints measured: ACTH, cortisol, FSH, LH, PRL, and TSH. Ipamorelin may influence other signaling pathways through GHS-R1a that were not measured in these early studies. Non-peptide GH secretagogues like the early compound L-692,585 also showed GH release with cortisol elevation in dose-dependent fashion, illustrating that most ghrelin receptor agonists have this problem and ipamorelin's selectivity is genuinely unusual, not the default.^[8]

The pairing of ipamorelin with CJC-1295, a GHRH analog that extends the GH pulse through a complementary receptor pathway, is one of the most common protocols in the growth hormone peptide space. This combination leverages ipamorelin's selective GH release alongside CJC-1295's sustained GHRH-receptor activation.

The Bottom Line

Ipamorelin's distinction among growth hormone releasing peptides is its pharmacological selectivity: it releases GH with potency comparable to GHRP-6 and GHRP-2 but does not increase ACTH, cortisol, or prolactin, even at doses 200 times higher than the effective GH-releasing concentration. This property, demonstrated in the 1998 Raun et al. study and confirmed in human PK/PD modeling by Gobburu et al. in 1999, makes ipamorelin a biased agonist at the ghrelin receptor, activating somatotroph signaling while sparing corticotroph and lactotroph pathways. The compound translates its GH release into tissue-level effects including dose-dependent bone growth in rats without desensitization. Long-term human data remains limited.

Frequently Asked Questions

Why is ipamorelin considered the cleanest growth hormone peptide?

Ipamorelin releases growth hormone without raising cortisol, ACTH, or prolactin, even at doses 200 times higher than the effective GH-releasing dose. Other GHRPs like GHRP-6 and GHRP-2 increase all three hormones alongside GH. This selectivity, demonstrated in the 1998 Raun et al. study in European Journal of Endocrinology, is unique among growth hormone releasing peptides.

Does ipamorelin raise cortisol levels?

No. In the landmark 1998 pharmacological study, ipamorelin did not increase ACTH or cortisol at any dose tested, including doses more than 200-fold above the effective GH-releasing concentration. This is in direct contrast to GHRP-6 and GHRP-2, which both elevate ACTH and cortisol alongside growth hormone.

How does ipamorelin compare to GHRP-6 for growth hormone release?

Both peptides release similar amounts of growth hormone. In swine, ipamorelin had an ED50 of 2.3 nmol/kg and maximal GH response of 65 ng/ml, while GHRP-6 showed an ED50 of 3.9 nmol/kg and Emax of 74 ng/ml. The key difference is that GHRP-6 also raises cortisol and stimulates strong appetite, while ipamorelin does neither.

What is ipamorelin's half-life in humans?

In human volunteers, ipamorelin has a terminal half-life of approximately 2 hours, with a clearance of 0.078 L/h/kg and volume of distribution of 0.22 L/kg. GH release peaks around 40 minutes after infusion and follows a single pulsatile episode, mimicking the body's natural GH secretion pattern. These pharmacokinetic parameters were established in a 1999 dose-escalation study.

Does ipamorelin cause hunger like GHRP-6?

No. GHRP-6 is known for causing intense hunger because it strongly activates the ghrelin receptor's appetite-signaling pathway. Ipamorelin binds the same receptor but appears to activate it in a biased manner that preferentially stimulates GH release from the pituitary without the strong central appetite drive that GHRP-6 produces.

How long has ipamorelin been studied?

Ipamorelin was first characterized in 1998 by Raun et al. at Novo Nordisk. Human pharmacokinetic data was published by Gobburu et al. in 1999. Animal studies on bone growth (Johansen et al., 1999) and GI motility (Venkova et al., 2009) followed. The compound has been studied for over 25 years, though long-term controlled human trials remain limited.